Subscribe To
Biovaxys technology says its french collaborator has excised the first tumors to produce 'dry runs' of its ovarian cancer vaccine
BioVaxys Technology Corp announced that its clinical study collaborator Hospices Civils de Lyon (HCL) in France has surgically excised the first ...
June 15, 2022, 9:29 am
Springworks therapeutics to present progress across the company's targeted oncology portfolio at virtual r&d day
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA's Real-Time Oncology Review (RTOR) Program, Expected in Second ...
June 10, 2022, 6:30 am
Rbc says verastem interim analysis in ovarian cancer reinforces enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 progr...
June 7, 2022, 2:35 pm
Immunogen (imgn) ovarian cancer drug bla gets priority review
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platin...
May 24, 2022, 11:18 am
Immunogen's stock is up 12% after the fda accepts application for new ovarian-cancer therapy
Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an ...
May 23, 2022, 7:59 am
Context therapeutics ends 1q with $45.7m as it gears up for 'pivotal' 2022
Context Therapeutics (NASDAQ:CNTX) Inc announced that it has ended its first quarter of 2022 with $45.7 million in cash and equivalents as of March 31...
May 11, 2022, 4:49 pm
Syros' cdk12 inhibitor shows anti tumor activity in preclinical studies
Syros Pharmaceuticals Inc (NASDAQ: SYRS) announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity ...
April 11, 2022, 9:30 am
Celsion and medidata to present findings on use of synthetic control arm to estimate treatment effect in ovarian cancer trial
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented...
April 6, 2022, 8:30 am
Clovis (clvs) up 24% on upbeat data from ovarian cancer study
Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment ...
April 4, 2022, 4:33 pm
Predictive oncology strengthens balance sheet in 2021; zpredicta acquisition highlights financial year
Predictive Oncology Inc. (NASDAQ:POAI) has reported its financial results for 2021, a year which saw the company strengthen its balance sheet, acquire...
April 1, 2022, 10:02 am
Clovis oncology: forging a fresh perspective
Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in th...
March 31, 2022, 7:23 pm
Clovis oncology's rubraca significantly improves pfs in ovarian cancer regardless of biomarker status
Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as ...
March 31, 2022, 9:34 am
Clovis oncology to seek fda approval for ovarian cancer drug as a maintenance therapy
Shares of Clovis Oncology Inc. CLVS, -3.51% soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival ...
March 31, 2022, 8:01 am
Nuformix says patent application for reformulated astrazeneca blockbuster has progressed to publication phase
Nuformix PLC (LSE:NFX) said its patent application for key asset NXP004 had progressed to the publication phase. Following this, it was able to reveal...
March 28, 2022, 2:56 am
Celsion corporation to hold year-end 2021 financial results and business update conference call on thursday, march 31, 2022
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-base...
March 24, 2022, 9:00 am
Why are immunogen shares trading lower today
ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resist...
March 21, 2022, 8:28 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ...
January 24, 2022, 9:48 am
Aim immunotech announces positive results from phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer
AIM ImmunoTech Inc (NYSE:AIM) announced positive data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ...
January 24, 2022, 9:48 am
Angle says study shows parsortix can select patients most suitable for immunotherapy treatments
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said pilot data from a study in ovarian cancer patients showed its Pa...
January 21, 2022, 3:30 am